Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary ...

A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well ...

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer

Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...
CURE

FDA Approves PD-L1 Test to Guide Keytruda Use in Esophageal and GEJ Cancer

U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...
EurekAlert!

Adjuvant PD-1/PD-L1 inhibitors show efficacy but highlight safety considerations in solid cancers

A new research paper was published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 ...

MSD secures EC clearance for Keytruda combination therapy for ovarian cancer

The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).
The Pharma Letter

Keytruda regimen wins EU nod in PD-L1-positive platinum-resistant ovarian cancer

Merck & Co’s Keytruda (pembrolizumab)—in combination with paclitaxel, with or without bevacizumab—has been approved in the ...
Oncology Nurse Advisor

In ES-SCLC, Adding PD-1/PD-L1 Inhibitors to Platinum-Etoposide Consistently Improves Survival

SCLC, researchers aimed to determine the consistency of benefit of adding PD-1/PD-L1 inhibitors to platinum-etoposide.
Business Wire

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the potential positive impact on the clinical development of its immunotherapy Multikine® (Leukocyte Interleukin, ...